Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04997161 · ClinicalTrials.gov registry record · Phase 4
Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
A Phase 4 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT04997161 is a Phase 4 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 3 participants.
The verdict
NCT04997161, a Phase 4 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
Prescribing Sodium zirconium cyclosilicate (SZC) with enhanced nutritional advice to participants with hyperkalaemia on haemodialysis will reduce serum K+ (S-K+ ) and enable the consumption of more fruit and vegetables and more satisfying diet. The study aims to show that participants using SZC achieve S-K+ reduction as well as participants on SoC (other than K+ binders), without the need for restricting K+ in the diet.
Interventions
- DRUG Sodium Zirconium Cyclosilicate (SZC)
- OTHER Enhanced dietary advice
- OTHER Standard dietary advice including K+ restriction.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-08-17 |
| Est. Completion | 2021-11-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04997161
The ClinicalTrials.gov registry entry for NCT04997161 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sodium Zirconium Cyclosilicate (SZC) is the first listed.
NCT04997161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04997161 about?
NCT04997161 is a clinical study titled "Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia". Prescribing Sodium zirconium cyclosilicate (SZC) with enhanced nutritional advice to participants with hyperkalaemia on haemodialysis will reduce serum K+ (S-K+ ) and enable the consumption of more fruit and vegetables and more satisfying diet. The study aims to show that participants using SZC achi...
What is the current status of trial NCT04997161?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2021-08-17. Estimated completion is 2021-11-17.
What interventions are being tested in trial NCT04997161?
The interventions under investigation include: Sodium Zirconium Cyclosilicate (SZC) (DRUG), Enhanced dietary advice (OTHER), Standard dietary advice including K+ restriction. (OTHER).
Who is sponsoring clinical trial NCT04997161?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.